CN1634084A - Compound isosorbide mononitrate injectio and its preparing process - Google Patents
Compound isosorbide mononitrate injectio and its preparing process Download PDFInfo
- Publication number
- CN1634084A CN1634084A CN 200410087647 CN200410087647A CN1634084A CN 1634084 A CN1634084 A CN 1634084A CN 200410087647 CN200410087647 CN 200410087647 CN 200410087647 A CN200410087647 A CN 200410087647A CN 1634084 A CN1634084 A CN 1634084A
- Authority
- CN
- China
- Prior art keywords
- injection
- isosorbide mononitrate
- aspirin
- injectio
- preparing process
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a compound isosorbide mononitrate injectio and its preparing process wherein the injection preparation comprises isosorbide mononitrate and aspirin, whose proportion is isosorbide mononitrate : aspirin = 1-99 : 99-1, the injection includes the forms of injection, freeze-dried powder injection, asepsis powder injection and high volume transfusion. The preparation can serve as a novel medicament for preventing angina pectoris caused by coronary arteriosclerosis or coronary arteriospasm.
Description
Technical field:
The invention provides a kind of compound isosorbide mononitrate injectio and preparation method thereof, belong to the technical field of medicine and preparation method thereof.
Background technology:
Isosorbide mononitrate is an antianginal drug.Be applicable to the chd prevention angina pectoris attacks, also be applicable to the treatment behind the myocardial infarction.Isosorbide mononitrate is the main active metabolite of sorbide nitrate.It can pass through to expand peripheral blood vessel on the one hand and increase the venous blood capacity, loads and the minimizing myocardial oxygen consumption before and after the reduction heart; Can improve the ischemic region supply of blood flow by the redistribution that promotes myocardial blood flow on the other hand.This product attracts rapidly, the bioavailability height, and effect is held time longer.Aspirin has antithrombotic characteristic in vivo: it can suppress Cycloxygenase, thromboxane and prostacyclin is generated reduce.With two kinds of pharmaceutical science prescriptions, be prepared into compound preparation, two medicines have the obvious synergistic effect.Both kept the loose vascular smooth muscle of isosorbide mononitrate, cause peripheral arterial and vein diastole, reduce venous backflow and cardiac load, promote the aerobic equilibrated important function of myocardial oxygen delivery, brought into play aspirin again and reduced the thrombotic effect of peripheral arterial internal congestion.Become a kind of novel cardio-cerebralvascular medicine.Isosorbide mononitrate aspirin compound oral administration preparation, existing clinically in recent years the application obtained satisfied curative effect.But injection type is not seen any report.And the injection more medicine that is clinical practice.Development isosorbide mononitrate aspirin compound injection becomes a clinical research topic of earnestly looking forward to.
Summary of the invention:
Purpose of the present invention is a blank of filling up isosorbide mononitrate aspirin compound injection, provides a kind of new drug and preparation method thereof safely and effectively for curing cardiovascular and cerebrovascular disease.Formation of the present invention is: compound recipe isosorbide mononitrate aspirin injection, formulated by isosorbide mononitrate and aspirin, its quantity relative ratio relationship is: isosorbide mononitrate: aspirin=1～99: 99～1.Its preferred proportioning is: isosorbide mononitrate: aspirin=60: 75.This injection is liquid and injectable powder.Its dosage form comprises isosorbide mononitrate aspirin injection, freeze-dried powder, aseptic powder injection, large capacity transfusion.Concrete preparation technology is: according to given ratio isosorbide mononitrate, aspirin are equipped with proper amount of water for injection, subsequent technique is prepared into injection, large capacity transfusion according to existing technology.Or above-mentioned solution dosed excipient such as mannitol, be made into freeze-dried powder or sterile powder injection by prior art.The present invention constitutes simply, the quality of production is controlled easily.Be easy to popularization, easy to use.The medicine of producing is applicable to the angina pectoris due to prevention coronary atherosclerosis or the coronary vasospasm.
Embodiment:
Embodiment 1: it is that aspirin 25 grams are formulated by isosorbide mononitrate 20 grams.Isosorbide mononitrate 20 grams, aspirin 25 grams are equipped with water for injection 2000ML, are made into injection according to prior art.Said preparation does not add any excipient.
Embodiment 2: it is that aspirin 25 grams are formulated, are equipped with water for injection 100000ML in the manufacturing process, make large capacity transfusion by prior art by isosorbide mononitrate 20 grams.
Embodiment 3: with isosorbide mononitrate 20 grams, it is an amount of that aspirin 25 grams are equipped with water for injection, is made into lyophilized injectable powder according to prior art.Can be in said preparation with mannitol as excipient.
Embodiment 4: it is that aspirin 25 grams are formulated by isosorbide mononitrate 20 grams.Be made into aseptic injection according to prior art.
Claims (5)
1, a kind of anginal compound recipe isosorbide mononitrate aspirin ejection preparation that is used to prevent due to coronary atherosclerosis or the coronary vasospasm, it is characterized in that: it is that its proportioning is: isosorbide mononitrate: aspirin=1～99: 99～1 by isosorbide mononitrate, the formulated injection of aspirin.
2, according to the described injection of claim 1, it is characterized in that: the optimization proportioning of said injection is: isosorbide mononitrate: aspirin=60: 75.
3, according to the described injection of claim 1, it is characterized in that: said injection is injection, freeze-dried powder, aseptic powder injection and large capacity transfusion.
4, according to the manufacture method of the described injection of claim 1: it is characterized in that: according to given ratio, isosorbide mononitrate, aspirin are equipped with proper amount of water for injection and adjuvant, and subsequent technique is to be made into ejection preparation according to prior art.
5, according to the manufacture method of the described injection of claim 4, it is characterized in that: in manufacturing process, the solubilizing agent that can add, cosolvent, excipient are other adjuvants that mannitol and pharmaceutics allow.Also can not add any solubilizing agent, cosolvent, excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410087647 CN1634084A (en) | 2004-11-24 | 2004-11-24 | Compound isosorbide mononitrate injectio and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410087647 CN1634084A (en) | 2004-11-24 | 2004-11-24 | Compound isosorbide mononitrate injectio and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1634084A true CN1634084A (en) | 2005-07-06 |
Family
ID=34847474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410087647 Pending CN1634084A (en) | 2004-11-24 | 2004-11-24 | Compound isosorbide mononitrate injectio and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1634084A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101816636A (en) * | 2010-03-20 | 2010-09-01 | 山东新时代药业有限公司 | Isosorbide mononitrate freeze-dried power injection and preparation method thereof |
| CN101708157B (en) * | 2009-12-08 | 2011-06-22 | 鲁南制药集团股份有限公司 | Isosorbide mononitrate sodium chloride injection |
| CN106619701A (en) * | 2016-12-07 | 2017-05-10 | 郑州郑先医药科技有限公司 | Western medicine composition for treating coronary heart disease and preparation method thereof |
-
2004
- 2004-11-24 CN CN 200410087647 patent/CN1634084A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101708157B (en) * | 2009-12-08 | 2011-06-22 | 鲁南制药集团股份有限公司 | Isosorbide mononitrate sodium chloride injection |
| CN101816636A (en) * | 2010-03-20 | 2010-09-01 | 山东新时代药业有限公司 | Isosorbide mononitrate freeze-dried power injection and preparation method thereof |
| CN106619701A (en) * | 2016-12-07 | 2017-05-10 | 郑州郑先医药科技有限公司 | Western medicine composition for treating coronary heart disease and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020158521A5 (en) | ||
| CN101584652B (en) | Risperidone sustained-release gel injection and preparation method thereof | |
| CN1665541A (en) | Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine | |
| CN1634084A (en) | Compound isosorbide mononitrate injectio and its preparing process | |
| US10780057B2 (en) | Casein-based silica dual drug-loading composite microcapsule and preparation method therefor | |
| CN100518730C (en) | Novel Subing drop pills and preparation method | |
| CN101185633A (en) | Neratinib sustained-release implant for treating solid tumor | |
| CN102284033A (en) | Preparation technology and production method of integrated novel Suoquan pill dosage form | |
| CN104841014B (en) | A kind of preparation method of the intravascular tissue engineering stent material for being loaded with pravastatin sodium | |
| CN1660420A (en) | Compound combination of Chinese traditional medicine in use for lowering viscosity of whole blood, thrombolysis and reducing blood fat | |
| CN101474164A (en) | Oral compound paclitaxel capsule and preparation method | |
| US20040228883A1 (en) | Prepackaged aqueous pharmaceutical formulation for the treatment of cardiac conditions containing at least two different active agents and method of formulation | |
| CN108310371B (en) | Blood fat reducing pharmaceutical composition and application thereof | |
| CN101176713B (en) | Carmustine sustained-release implantation agent for curing entity tumour | |
| JPH09512280A (en) | Camptothecin or 7-ethylcamptothecin lactone stabilizing drug | |
| CN107961237A (en) | Compound isosorbide mononitrate injectio and preparation method thereof | |
| CN102283984A (en) | Preparation technology of integrated novel Gualou Xiebai Baijiu decoction dosage form | |
| RU2005113980A (en) | STRENGTHENING ALCOHOL METABOLISM | |
| CN1176658C (en) | Aseptic freeze-dried prostaglandin injection and its preparing method and use | |
| CN102274164A (en) | Sustained release gel for injection for paliperidone and paliperidone derivative | |
| CN1634551A (en) | Compound piracetam and cerebroprotein hydrolysate medicine preparation and method for preparing the same | |
| CN101062406A (en) | Reeombinnt human granulocyte colony stimulating factor microemulsion | |
| CN1875979B (en) | Soft capsule of hippophae rhamnoides and preparation process thereof | |
| CN1634508A (en) | Saussurea involucrata drop pill and its preparation method | |
| CN1187054C (en) | Osmosis pump controlled release preparation contg. Chinese medicine of cyclovirobuxine D, and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |